A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.
Bleehen
N M
NM
University Department, Addenbrooke's Hospital, Cambridge, UK.
Calvert
A H
AH
Lee
S M
SM
Harper
P
P
Kaye
S B
SB
Judson
I
I
Brampton
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D014226:Triazenes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014226:Triazenes; C030838:1-(4-carboxyphenyl)-3,3-dimethyltriazene